Tech Company Financing Transactions
TCR2 Therapeutics Funding Round
TCR2 Therapeutics, based in Cambridge, raised $125 million from 6 Dimensions Capital, Alexandria Venture Investments and ArrowMark Partners.
Transaction Overview
Company Name
Announced On
3/22/2018
Transaction Type
Venture Equity
Amount
$125,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds of the financing will be used to advance two TRuC-T cell programs through human proof-of-concept, including its lead solid tumor program TC-210 targeting mesothelin.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
100 Binney St. 710
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
TCR2, Inc. (Nasdaq: TCRR) is a pharmaceutical company focused on engineering T cells for cancer therapy.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Garry Menzel
Chief Financial Officer
Ian Somaiya
Chief Medical Officer
Alfonso Cardama
Chief Scientific Officer
Robert Hofmeister
VP - Bus. Development
Andrew Cornforth
VP - Operations
Amy Lynch
VP - R & D
Daniel Getts
Browse more venture capital transactions:
Prev: 3/22/2018: Mamava venture capital transaction
Next: 3/22/2018: Align venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs